Bharat Parenterals Ltd Share Price & Stock Analysis

Bharat Parenterals Ltd (BSE: 541096) is a Vadodara, Gujarat-based company in the Medicinal Chemicals and Botanical Products industry. With a market capitalisation of ₹1,316 Cr, it ranks #1,452 by market cap among the 6,197 Indian listed companies on FinBizNet, and #44 of 86 in Medicinal Chemicals and Botanical Products. At ₹1,900.00 (as of 16 Nov 2026), the share price is 17.2% below its 52-week high of ₹2,295.10 and 58.2% above its 52-week low of ₹1,201.10. The share price is up 7.6% over one year and up 15.7% over three months.

Key Metrics

Current Price₹1,900.00
Market Cap₹1,316 Cr
BSE Code541096
SectorHealth Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals
Sub-IndustryBiotechnology and Life Sciences > Medicinal Chemicals and Botanical Products
P/E RatioNot meaningful (loss)
Return on Equity4.06%
Return on Assets-1.82%
52-Week Range₹1,201.10 – ₹2,295.10
1-Year Price Change+7.6%
3-Month Price Change+15.7%
Beta (1Y)0.71
Dividend Yield0.05%
HeadquartersVadodara, Gujarat
Websitebplindia.in

Latest Quarterly Results — Q1 FY27

Revenue₹56 Cr
Net Profit₹4 Cr
Net Margin6.6%
EPS (Basic)₹5.31
Basisstandalone

Figures in ₹ crore, parsed from the company's exchange filing (XBRL).

Bharat Parenterals Ltd Quarterly Revenue and Profit Trend

Bharat Parenterals Ltd reported revenue of ₹56 Cr in Q1 FY27, down 41.2% from ₹94 Cr in Q1 FY26 and down 1.8% from ₹57 Cr in Q4 FY26. It posted a net profit of ₹4 Cr for the quarter, against a net profit of ₹10 Cr in Q1 FY26 (down 63.4%). Across the 8 quarters from Q2 FY25 to Q1 FY27, quarterly revenue ranged from ₹41 Cr (Q3 FY26) to ₹94 Cr (Q1 FY26). The company was profitable in each of these 8 quarters.

QuarterRevenueNet ProfitNet Margin
Q1 FY27₹56 Cr₹4 Cr6.6%
Q4 FY26₹57 Cr₹1 Cr2.4%
Q3 FY26₹41 Cr₹2 Cr4.6%
Q2 FY26₹42 Cr₹3 Cr6.5%
Q1 FY26₹94 Cr₹10 Cr10.6%
Q4 FY25₹80 Cr₹2 Cr2.8%
Q3 FY25₹67 Cr₹7 Cr9.7%
Q2 FY25₹64 Cr₹5 Cr8.5%

Standalone figures (₹ crore, XBRL filings).

Shareholding and Delivery

Promoters held 51.14% of Bharat Parenterals Ltd's shares as of Mar 2026, unchanged from Mar 2025. Delivery averaged 45.0% of traded volume across 16 NSE sessions (22 Oct 2026 – 13 Nov 2026).

About Bharat Parenterals Ltd

Bharat Parenterals Limited engages in the research, development, manufacturing, marketing, sourcing, and distribution of pharmaceutical products in India and internationally. The company provides antibiotics, cardiovascular and central nervous system, antifungal, antimalarial, gastrointestinal tract/alimentary systems, analgesics, anaesthetics, quinolones, erectile dysfunction medicines, nutritional supplements, steroids and hormones, and other drugs. It also engages in manufacturing of general products in capsules, tablets, ointment and creams, injections, oral liquids, and powder sachets forms; and beta lactum and cephalosporin products in capsules, tablets, dry syrup, and powder for injection forms. In addition, it offers eye drops. Bharat Parenterals Limited was incorporated in 1992 and is based in Vadodara, India.

Products and Services

1. Manufacturing of Pharmaceuticals Formulations-This segment manufactures and sells pharmaceutical formulations. It offers products in the areas of anti retroviral, cephalosporins antibiotics, antiprotozoal/anthelmintic, respiratory, antiallergic/anti histaminic/anticold, cleansing agents/skin infections, antibiotic, cardiovascular systems, anti diabetic, anti tuberculosis, anti-fungal, antimalarial, gastroinestinaltract/alimentary systems, antiinflammatory/anti pyretic/analgesics, supplements, central nervous system, anaesthetics, anti viral, steroids and hormones, uterine stimulant, anticancer, and other.

Business Segments

1. Manufacturing Of Pharma Products-61.1% 2. Trading Of Pharma Products-18% 3. Contract Development And Manufacturing Operations-20.9%

Bharat Parenterals Ltd vs Peers — Medicinal Chemicals and Botanical Products

CompanyMarket CapP/EROELatest Qtr Revenue1Y Change
Sun Pharmaceutical Industries Limited₹4,56,425 Cr39.514.72%₹16,199 Cr+11.2%
Laurus Labs Ltd₹1,31,242 Cr145.617.74%₹2,206 Cr+146.8%
Zydus Lifesciences Ltd₹1,19,651 Cr24.118.32%₹7,910 Cr+26.0%
Dr.Reddys Lab₹1,15,464 Cr26.911.52%₹8,698 Cr+14.5%
Cipla Limited₹1,14,712 Cr29.311.74%₹7,404 Cr-7.6%
Mankind Pharma₹1,09,870 Cr5712.45%₹4,338 Cr+16.7%
Aurobindo Pharma Ltd.₹1,05,150 Cr309.93%₹10,263 Cr+59.8%
Lupin Ltd₹92,087 Cr17.326.91%₹7,827 Cr+0.4%
Bharat Parenterals Ltd₹1,316 Crn/m4.06%₹56 Cr+7.6%

Listed by market capitalisation. Ratios are shown for context only.

Frequently Asked Questions

What is the current share price of Bharat Parenterals Ltd?

Bharat Parenterals Ltd is trading at ₹1,900.00, with a market capitalisation of ₹1,316 Cr.

Which sector does Bharat Parenterals Ltd belong to?

Bharat Parenterals Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products).

What are the key financial ratios of Bharat Parenterals Ltd?

Bharat Parenterals Ltd has a return on equity of 4.06%.

What is the stock symbol of Bharat Parenterals Ltd?

Bharat Parenterals Ltd is listed on the BSE under the scrip code 541096.

How has Bharat Parenterals Ltd's share price moved over the past year?

Bharat Parenterals Ltd's share price is up 7.6% over one year and up 15.7% over three months. Its 52-week range is ₹1,201.10 to ₹2,295.10.

What were Bharat Parenterals Ltd's latest quarterly results?

In Q1 FY27, Bharat Parenterals Ltd reported revenue of ₹56 Cr and net profit of ₹4 Cr, with basic EPS of ₹5.31 (standalone, parsed from the company's exchange filing).

How have Bharat Parenterals Ltd's revenue and profit changed over the past year?

Bharat Parenterals Ltd reported revenue of ₹56 Cr in Q1 FY27, down 41.2% from ₹94 Cr in Q1 FY26 and down 1.8% from ₹57 Cr in Q4 FY26.

What is the promoter holding in Bharat Parenterals Ltd?

Promoters held 51.14% of Bharat Parenterals Ltd's shares as of Mar 2026, unchanged from Mar 2025.

More on FinBizNet

Data as of 16 Nov 2026. Descriptive market data only — not investment advice.